Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXUS study of perioperative encorafenib + binimetinib + cetuximab for resectable BRAF V600E-mutant colorectal metastasis
jRCT2031220025Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 1-year progression-free survival. Started Sep 2022; status: active, not recruiting.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2031220025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220025.